Clinical Studies

Advances in Pharmacology

Volumn 52, Issue , 2005, Pages 289-320

  Young, Andrew ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; ANTIDIABETIC AGENT; PRAMLINTIDE;

ANIMAL; CLINICAL TRIAL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

AMYLOID; ANIMALS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 33645210308     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(05)52018-0     Document Type: Review

References (154)

1. Anonymous. Humalog: Insulin Lispro Injection (rDNA origin) [package insert] (1996), Eli Lilly and Company, Indianapolis, IN
2. Anonymous. Pramlintide: (AC 137, AC 0137, Symlin trade mark, Tripro-Amylin). BioDrugs 17 (2003) 73-79
3. Amiel S.A., Heller S.R., Mac Donald I.A., Schwartz S.L., Klaff L.J., Ruggles J.A., Weyer C., Kolterman O.G., and Maggs D.G. The effect of pramlintide on hormonal, metabolic, or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabet. Obes. Metab. 7 (2005) 504-516
4. TM™ (pramlintide acetate) injection [package insert] (2005), Amylin Pharmaceuticals Inc, San Diego, CA
5. Armbruster D.A. Fructosamine: Structure, analysis, and clinical usefulness. Clin. Chem. 33 (1987) 2153-2163
6. Bone H.G., Hurley M.A., Goldstein H., Fineman M.S., and Kolterman O.G. Effects of administration of pramlintide for 12 months on bone metabolism markers in people with type 1 diabetes. Program and Abstracts, Endocrine Society 81st Annual Meeting, June 12-15, San Diego, Calif (1999) 447
7. Borm A.K., Klevesath M.S., Borcea V., Kasperk C., Seibel M.J., Wahl P., Ziegler R., and Naworth P.P. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Horm. Metab. Res. 31 (1999) 472-475
8. Bretherton-Watt D., Gilbey S.G., Ghatei M.A., Beacham J., and Bloom S.R. Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia 33 (1990) 115-117
9. Bunn H.F., Gabbay K.H., and Gallop P.M. The glycosylation of hemoglobin: Relevance to diabetes mellitus. Science 200 (1978) 21-27
10. Burrell T.A., Fineman M.S., Deckhut D., Weyer C., McIntyre S., Wang Y., Lutz K., Nielsen L.L., and Kolterman O.G. Mealtime subcutaneous (SC) injection of pramlintide slows without arresting gastric emptying in patients with type 2 diabetes. Diabet. Metab. 29 (2003) 4S124-4S125
11. Buse J.B., Weyer C., and Maggs D.G. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clin. Diabet. 20 (2002) 137-144
12. Chapman I., Parker B., Doran S., Feinle-Bisset C., Wishart J., Wang Y., Gao H.-Y., McIntyre S., Burrell T., Deckhut D., Weyer C., and Horowitz M. Effect of pramlintide on ad-libitum food intake in obese subjects and subjects with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over study. Diabetes 53 suppl. 2 (2004) A82
13. Colburn W.A., Gottlieb A.B., Koda J., and Kolterman O.G. Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J. Clin. Pharmacol. 36 (1996) 13-24
14. Cooper G.J.S. Amylin and insulin co-replacement therapy for insulin-dependent (type I) diabetes mellitus. Med. Hypotheses 36 (1991) 284-288
15. Cooper M.E., McNally P.G., Phillips P.A., and Johnston C.I. Amylin stimulates plasma renin concentration in humans. Hypertension 26 (1995) 460-464
16. DCCT Research, Group. The Diabetes Control and Complications Trial (DCCT): Design and methodologic considerations for the feasibility phase. Diabetes 35 (1986) 530-545
17. DCCT Research, Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann. Intern. Med. 122 (1995) 561-568
18. DCCT Research, Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann. Neurol. 38 (1995) 870-880
19. DCCT Research, Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch. Ophthalmol. 113 (1995) 36-51
20. DCCT Research, Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 102 (1995) 647-661
21. Diabetes, Control and Complications, Trial (DCCT) Research, Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am. J. Cardiol. 75 (1995) 894-903
22. Dobbs R., Sakurai H., Sasaki H., Faloona G., Valverde I., Baetens D., Orci L., and Unger R. Glucagon: Role in the hyperglycemia of diabetes mellitus. Science 187 (1975) 544-547
23. Edelman S.V., and Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: Potential benefit of replacing amylin, a second β-cell hormone. Diabet. Technol. Ther. 4 (2002) 175-189
24. Fineman M., Kolterman O., Thompson R., and Koda J. Glucagon secretion in patients with type I diabetes was inhibited by the human amylin analogue, pramlintide. Diabet. Med. 14 (1997) S29
25. Fineman M., Kolterman O., Thompson R., and Koda J. The human amylin analogue pramlintide inhibited glucagon secretion in type I diabetic subjects. 79th Annual Meeting of the Endocrine Society, Program and Abstracts (1997) 472
26. Fineman M., Kolterman O., Thompson R., and Koda J. Pramlintide, a human amylin analogue, inhibited glucagon secretion in patients with type I diabetes. Can. J. Diabet. Care 21 (1997) 26
27. Fineman M., Kolterman O., Thompson R., and Koda J. The human amylin analogue pramlintide inhibited glucagon secretion in type I diabetic subjects. Diabetes 40 (1997) 30A
28. Fineman M., Koda J., and Kolterman O. Subcutaneous administration of a human amylin analogue suppresses postprandial plasma glucagon concentrations in type I diabetic patients. Diabetes 47 (1998) A89
29. Fineman M., Kolterman O., Thompson R., and Koda J. Pramlintide, a human amylin analogue, inhibited glucagon secretion in patients with type 1 diabetes. AACE Back to the Future: A Renaissance in Endocrinology, 1998 Syllabus American Association of Clinical Endocrinologists Seventh Annual Meeting and Clinical Congress, April 28-May 3, 1998, Buena Vista Palace, Orlando, Florida (1998) 112
30. Fineman M., Organ K., and Kolterman O. The human amylin analogue pramlintide suppressed glucagon secretion in patients with type 2 diabetes. Diabetologia 41 (1998) A167
31. Fineman M., Bahner A., Gottlieb A., and Kolterman O. Effects of six months administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 1 diabetes. Diabetes 48 suppl. 1 (1999) A113
32. Fineman M., Bahner A., Gottlieb A., and Kolterman O. Effects of six months' administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 2 diabetes. Endocrine Society 81st Annual Meeting Program and Abstracts (1999) 471-472
33. Fineman M., Gottlieb A., Bahner A., Parker J., Waite G., and Kolterman O. Pramlintide therapy in addition to insulin in type 1 diabetes: Effect on metabolic control after 6 months. Diabetologia 42 suppl. 1 (1999) A232
34. Fineman M., Gottlieb A., Skare S., and Kolterman O. 52 weeks of pramlintide therapy as an adjunct to insulin improved metabolic control in people with type 2 diabetes. Diabetologia 43 (2000) (abstract 783).
35. Fineman M., Gottlieb A., Skare S., and Kolterman O. Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 2 diabetes during treatment for 52 weeks. Diabetes 49 (2000) A106
36. Fineman M., Maggs D., Burrell T., Velte M., and Kolterman O. Addition of pramlintide to insulin therapy in type 1 diabetes: Impact on glycemic and weight control stratified by BMI. Diabetes 50 suppl. 2 (2001) A112
37. Fineman M., Weyer C., Maggs D.G., Strobel S., and Kolterman O.G. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm. Metab. Res. 34 (2002) 504-508
38. Ghatei M.A., Datta H.K., Zaidi M., Bretherton-Watt D., Wimalawansa S.J., Mac Intyre I., and Bloom S.R. Amylin and amylin-amide lack an acute effect on blood glucose and insulin. J. Endocrinol. 124 (1990) R9-R11
39. Gilbey S.G., Bretherton-Watt D., Beacham J., Ghatei M.A., and Bloom S.R. High dose amylin in man: Unexpected failure to affect intravenous glucose tolerance. BDA Diabet. Med. 6 (1989) 5A
40. Gilbey S., Ghatei M.A., Bretherton-Watt D., Jones P.M., Beacham I., Perera T., Girgis S., Bloom S.R., and Zaidi M. Amylin lowers serum calcium in Paget's bone disease: Further evidence for a role in calcium metabolism. J. Bone Miner. Res. 6 (1991) S293
41. Gottlieb A., Fineman M., Bahner A., Parker J., Waite G., and Kolterman O. Pramlintide therapy in addition to insulin in type 2 diabetes: Effect on metabolic control after 6 months. Diabetologia 42 suppl. 1 (1999) A232
42. Gottlieb A., Velte M., Fineman M., and Kolterman O. Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks. Diabetes 49 (2000) A109
43. Gottlieb A., Velte M., Fineman M., and Kolterman O. Pramlintide treatment for 52 weeks improved glycemic and weight control in people with type 1 diabetes. Diabetologia 43 (2000) A47
44. Heinemann L., Heise T., Maggs D., McKay R., Ruggles J., Wang Y., Burrell T., and Weyer C. Pramlintide does not impair symptomatic or catecholaminergic responses to hypoglycemia. Diabet. Metab. 29 (2003) 4S264
45. Heise T., Heinemann L., and Weyer C. Amylin-substitution with pramlintide as conjunction to insulin therapy. Diabet. Stoffwechsel 11 (2002) 233-244
46. Heise T., Heinemann L., Maggs D., McKay R., Ruggles J., Wang Y., Burrell T., and Weyer C. Pramlintide does not impair symptomatic or catecholaminergic responses to hypoglycemia. Diabetes 52 suppl. 1 (2003) A463
47. Heise T., Heinemann L., Heller S., Weyer C., Wang Y., Strobel S., Kolterman O., and Maggs D. Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism 53 (2004) 1227-1232
48. 1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabet. Obes. Metab. 5 (2003) 408-414
49. Hollander P.A., Levy P., Fineman M.S., Maggs D.G., Shen L.Z., Strobel S.A., Weyer C., and Kolterman O.G. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial. Diabet. Care 26 (2003) 784-790
50. Hollander P., Maggs D.G., Ruggles J.A., Fineman M., Shen L., Kolterman O.G., and Weyer C. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes. Res. 12 (2004) 661-668
51. Jeffcoate S., Schoenfeld S., Blonde L., and Kolterman O. Sustained weight loss after 1 year of pramlintide therapy in both type 1 and type 2 diabetes. Int. J. Obes. Relat. Metab. Disord. 22 (1998) S268
52. Kawamori R., Shichiri M., Kikuchi M., Yamasaki Y., and Abe H. The mechanism of exaggerated glucagon response to arginine in diabetes mellitus. Diabet. Res. Clin. Pract. 1 (1985) 131-137
53. Koda J., Fineman M., Percy A., Blase E., and Lillioja S. Use of a new two-site immunoassay for amylin to characterize amylin hormone response in Pima Indians. Diabetologia 36 (1993) A137
54. Kolterman O., Gottlieb A., and Moyses C. Amylin agonist, AC-137, reduces postprandial hyperglycemia in subjects with insulin dependent diabetes mellitus (IDDM). Diabetes 43 (1994) 78A
55. Kolterman O.G., Gottlieb A.B., and Moyses C.J. Administration of tripro-amylin reduces postprandial hyperglycemia in subjects with juvenile-onset diabetes. Diabetologia 37 (1994) A72
56. Kolterman O.G., Gottlieb A., Moyses C., and Colburn W. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabet. Care 18 (1995) 1179-1182
57. Kolterman O.G., Gottlieb A.B., Organ K.A., and Thompson R.G. Reduction of postprandial hyperglycemia in patients with type II diabetes by the human amylin analogue AC137. Diabetologia 38 (1995) A193
58. Kolterman O., Fineman M., Burrell T., Strobel S., Shen L., and Maggs D. Adjunctive therapy with pramlintide lowered A1c without an increase in overall severe hypoglycemia event rate in patients with type 1 diabetes approaching ADA glycemic targets. Diabetes 52 suppl. 1 (2003) A124
59. Kolterman O., Kisicki J.C., Peltier L., Gottlieb A., and Moyses C. Infusion of amylin agonist AC-0137 reduces postprandial hyperglycemia in subjects with type 1 diabetes (IDDM). Clin. Res. 42 (1994) 87A
60. Kolterman O., Organ K., and Gottlieb A. Intravenous (IV) infusion of the human amylin analogue, AC 137, reduces postprandial hyperglycemia (PPH) in subjects with type I diabetes mellitus receiving oral nutrients but not IV glucose. Diabetes 44 (1995) 127A
61. Kolterman O.G., Pearson L., Peterson J., Gottlieb A., and Thompson R.G. Pramlintide, a human amylin analog, improved glucose control independent of entry HbA1c. Diabetes 45 (1996) 289A
62. Kolterman O., Peterson J., and Gottlieb A. Subcutaneous administration of AC137, a human amylin analogue, reduces postprandial hyperglycemia (PPH) in subjects with type I diabetes mellitus. Diabetes 44 (1995) 57A
63. Kolterman O.G., Schwartz S., Corder C., Levy B., Klaff L., Peterson J., and Gottlieb A. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 39 (1996) 492-499
64. Kolterman O.G., and Schoenfeld S.L. Intravenous pramlintide reduces postprandial hyperglycemia and C-peptide concentrations in people with type II diabetes mellitus. American Association of Clinical Endocrinologists (AACE) Sixth Annual Meeting and Clinical Congress (1997) 124
65. Kolterman O.G., and Schoenfeld S.L. Pramlintide reduces 24-hour glucose and serum fructosamine concentrations in people with type I diabetes mellitus. American Association of Clinical Endocrinologists (AACE) Sixth Annual Meeting and Clinical Congress (1997) (abstract 8).
66. Kolterman O., Whitehouse F., Ratner R., Rosenstock J., Schoenfeld S., and Jeffcoate S. Positive effects on body weight resulting from pramlintide therapy in type 1 and type 2 diabetes. Diabetologia 41 (1998) A214
67. Kolterman O., Whitehouse F., Ratner R., Rosenstock J., Schoenfeld S., and Jeffcoate S. Positive effects on body weight resulting from pramlintide therapy in type 1 and type 2 diabetes. Can. J. Diabet. Care 22 (1998) A13
68. Kolterman O., Bahner A., Gottlieb A., and Fineman M. Pramlintide (human amylin analogue) as an adjunct to insulin therapy in patients with type 1 diabetes improved glycemic control over 2 years. Diabetes 48 (1999) A104-A105
69. 1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type1 diabetes approaching glycemic targets. Diabetologia 45 suppl. 2 (2002) A240
70. Kolterman O., Maggs D., Burrell T., Strobel S., Brown D., and Weyer C. Pramlintide, as an adjunct to insulin therapy, led to improved control of both glycemia and weight in African American and Hispanic patients with type 2 diabetes. Diabetes 52 suppl. 1 (2003) A124
71. Kolterman O., Maggs D., Burrell T., Strobel S., Brown D., and Weyer C. Pramlintide, as an adjunct to insulin therapy, led to improved control of both glycemia and weight in African American and Hispanic patients with type 2 diabetes. Diabet. Metab. 29 (2003) 4S265
72. Kolterman O., Burrell T., Shen L., et al. Initiation of pramlintide using dose-titration in intensively-treated patients with type 1 diabetes resulted in mitigation of nausea and hypoglycemia. Late-breaking abstract presented at: American Diabetes Association 63rd Scientific Sessions; June 13-17, 2003; New Orleans, LA (2003)
73. Kong M.F., King P., Macdonald I., Stubbs T., Perkins A., and Tattersall R. Pramlintide reduced postprandial hyperglycaemia by slowing the delivery of meal-derived glucose. Diabet. Med. 14 (1997) S47-S48
74. Kong M.F., King P., Macdonald I.A., Stubbs T.A., Perkins A.C., Blackshaw P.E., Moyses C., and Tattersall R.B. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 40 (1997) 82-88
75. Kong M.F., Stubbs T., King P., Lambourne J., Madonald I., Blackshaw E., Perkins A., and Tattersall R. The effect of single doses of pramlintide on gastric emptying of two meals in IDDM. Diabetes 40 (1997) 154A
76. Kovatchev B., Cox D.J., McCall A., Crean J., Gloster M., and Whitehouse F. Effects of pramlintide on the magnitude and speed of postprandial blood glucose fluctuations in patients with type 1 diabetes. Diabetes 53 suppl. 2 (2004) A133
77. Kruger D.F., and Gloster M.A. Pramlintide for the treatment of insulin-requiring diabetes mellitus: Rationale and review of clinical data. Drugs 64 (2004) 1419-1432
78. Levetan C., Want L., Weyer C., Crean J., Strobel S., Wang Y., Maggs D.G., Schoenamsgruber E., Kolterman O.G., Chandran M., Mudaliar S., and Henry R.R. Reduced glucose fluctuations following 4 weeks of pramlintide treatment in patients with type 1 diabetes intensively treated with insulin pumps. Diabetes 51 suppl. 1 (2002) A106
79. Levetan C., Want L.L., Weyer C., Strobel S.A., Crean J., Wang Y., Maggs D.G., Kolterman O.G., Chandran M., Mudaliar S.R., and Henry R.R. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglycerides excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabet. Care 26 (2003) 1-8
80. Macdonald I., King P., Kong M.-F., Stubbs T., Perkins A., Moyses C., and Tattersall R. Infusion of the human amylin analogue, AC137, delays gastric emptying in men with IDDM. Diabetologia 38 suppl. 1 (1995) A32
81. Maggs D., Burrell T., Fineman M., and Kolterman O. Pramlintide as adjunctive treatment to insulin in type 2 diabetes resulted in improved glycemic control and concomitant weight loss. Diabetes 50 suppl. 2 (2001) A124-A125
82. Maggs D., Fineman M., Burrell T., Gottlieb A., and Kolterman O.G. In type 1 diabetes, addition of pramlintide to insulin therapy resulted in long-term glycemic improvement without the increase in severe hypoglycemia noted in patients treated with insulin alone. Diabetes 50 suppl. 2 (2001) A442
83. Maggs D.G., Weyer C., Burrell T., Gottlieb A.D., Shen L.Z., and Kolterman O.G. Amylin replacement with pramlintide as an adjunct to insulin therapy facilitates a combined improvement in glycemic and weight control in type 2 diabetes. Diabetologia 44 suppl. 1 (2001) A237
84. Maggs D., Weyer C., Crean J., Wang Y., Burrell T., Fineman M., Kornstein J., Schwartz S., Guiterrez M., and Kolterman O. Mealtime amylin replacement with pramlintide markedly improves postprandial glucose excursions when added to insulin lispro in patients with type 2 diabetes: A dose-timing study. Diabetologia 45 suppl. 2 (2002) A264
85. Maggs D., Shen L., Strobel S., Brown D., Kolterman O., and Weyer C. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: A pooled post hoc analysis. Metabolism 52 (2003) 1638-1642
86. Maggs D.G., Fineman M., Kornstein J., Burrell T., Schwartz S., Wang Y., Ruggles J.A., Kolterman O.G., and Weyer C. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: A dose timing study. Diabet. Metab. Res. Rev. 20 (2004) 55-60
87. Marrero D., Kruger D., Burrell T., Gloster M., Crean J., Herrmann K., and Kolterman O. Patients with type 1 diabetes: Perceptions associated with pramlintide as an adjunctive treatment to insulin. Endocr. Pract. 10 suppl. 1 (2004) 44
88. Marrero D., Kruger D., Burrell T., Gloster M., Crean J., Herrmann K., and Kolterman O. Patients with type 1 diabetes: Perceptions associated with pramlintide as an adjunctive treatment to insulin. Diabetes 53 suppl. 2 (2004) A137-A138
89. McCall A., Kovatchev B.P., Cox D.J., Crean J., and Gloster M. Assessing glucose variability using CGMS in pramlintide- and placebo-treated subjects with type 1 diabetes mellitus. Diabetes 53 suppl. 2 (2004) A138
90. McNally P.G., Phillips P.A., Johnston C.I., and Cooper M.E. Human amylin increases plasma renin in man: A possible explanation for the association between hypertension and insulin resistance?. Program and Abstracts, the Endocrine Society, 76th Annual Meeting; 1994 Jun 15-16; Ahaheim, CA (1994) Abstract 286
91. McNally P.G., Phillips P.A., Johnston C.I., Kolterman O.G., and Cooper M.E. Human amylin increases plasma renin in man: A possible link between hypertension and insulin resistance?. Diabetologia 37 (1994) A46
92. Moyses C., Kolterman O., and Mant T. Pharmacokinetics and hyperglycaemic effects of the amylin analogue, AC137, in man. Diabet. Med. 10 (1993) S25
93. Moyses C., Kolterman O., Nuttall A., and Mant T. First administration to man of the human amylin analogue tripro-amylin. Diabetologia 37 (1994) A72
94. Müller W.A., Faloona G.R., Aguilar-Parada E., and Unger R.H. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N. Engl. J. Med. 283 (1970) 109-115
95. Nuttall A., Bryan G.L., and Moyses C. Administration of human amylin increases plasma renin activity and plasma aldosterone in man. Am. J. Hypertens. 8 (1995) 108A
96. Nuttall A., Bryan G.L., and Moyses C. Intravenous human amylin increases plasma renin activity and plasma aldosterone in man. Eur. Heart J. 16 (1995) 66
97. Nyholm B., Moller N., Bryan G., Moyses C., and Alberti K.G.M.M. Acute effects of the amylin analogue AC-0137 on fuel metabolism in patients with IDDM. Diabetes 44 (1995) 255A
98. Nyholm B., Moller N., Bryan G., Moyses C., Alberti K.G.M.M., and Schmitz O. Acute metabolic effects of the amylin analogue AC137 in patients with insulin-dependent diabetes mellitus. Diabetologia 38 (1995) A193
99. Nyholm B., Moller N., Gravholt C.H., Orskov L., Mengel A., Bryan G., Moyses C., Alberti K.G., and Schmitz O. Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81 (1996) 1083-1089
100. Nyholm B., Orskov L., Hove K., Gravholt C., Moller N., Alberti N., and Schmitz O. The amylin analogue pramlintide decreases post-prandial plasma glucose and glucagon in IDDM. Diabetes 46 (1997) 155A
101. Nyholm B., Orskov L., Hove K.Y., Gravholt C.H., Moller N., Alberti K.G.M.M., and Schmitz O. The amylin analogue pramlintide decreases postprandial plasma glucose and glucagon in IDDM patients. Diabetologia 40 (1997) A46
102. Nyholm B., Orskov L., and Schmitz O. The amylin analogue pramlintide decreased post-prandial plasma glucose and glucagon in patients with type I diabetes. Diabet. Med. 14 (1997) S29
103. Nyholm B., Orskov L., Hove K., Gravholt C., Moller N., Alberti K., Moyses C.K.O., and Schmitz O. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 48 (1999) 935-941
104. Orskov L., Nyholm B., Hove K., Gravholt C., Moller N., Kolterman O., Alberti K., and Schmitz O. Effects of the amylin analogue pramlintide on the glucose response to a glucagon challenge in IDDM. Diabetologia 40 (1997) A355
105. Orskov L., Nyholm B., Hove K.Y., Gravholt C.H., Moller O., Kolterman O., Alberti K.G.M.M.A., and Schmitz O. Effects of the amylin analogue pramlintide on the glucose response to a glucagon challenge in IDDM. Diabetes 46 (1997) 155A
106. Orskov L., Nyholm B., Yde Hove K., Gravholt C.H., Moller N., and Schmitz O. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects. Diabet. Med. 16 (1999) 867-874
107. Parker J., Kong M.F., Stubbs T., King P., Lambourne J., Macdonald I., Blackshaw E., Perkins A., and Tattersall R. Single subcutaneous doses of pramlintide and gastric emptying of two meals in type I diabetes. Diabet. Med. 15 suppl. 1 (1998) S50
108. Percy A.J., Trainor D., and Koda J. Development of a sensitive two-site immunoassay and its use for monitoring amylin levels in normal individuals. Abstract presented at American Diabetes Association Southern California Research Symposium; Irvine, CA (1993)
109. Petry C.J., Percy A., Koda J.E., and Hales C.N. Development of sensitive two-site immunoassays for rat amylin. Proceedings of the ACB National Meeting (1995) 75
110. Raskin P., Aydin I., and Unger R.H. Effect of insulin on the exaggerated glucagon response to arginine stimulation in diabetes mellitus. Diabetes 25 (1976) 227-229
111. Ratner R., Levetan C., Schoenfeld S., Jeffcoate S., and Kolterman O. Effects of pramlintide therapy: A 1-year study in insulin-requiring type 2 diabetes. Diabetologia 41 (1998) A61
112. Ratner R.E., Want L.L., Fineman M.S., Velte M.J., Ruggles J.A., Gottlieb A., Weyer C., and Kolterman O.G. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabet. Technol. Ther. 4 (2002) 51-61
113. Ratner R.E., Dickey R., Fineman M., Maggs D.G., Shen L., Strobel S.A., Weyer C., and Kolterman O.G. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: A 1-year randomized controlled trial. Diabet. Med. 21 (2004) 1204-1212
114. Redalieu E., Thompson R.G., Dean E., Petrella E., Musunuri S., and Gottlieb A. Pharmacokinetics of pramlintide and free insulin following combined or separate injections in patients with type I diabetes. Diabetes 45 (1996) 220A
115. Redalieu E., Blake D., Nuttall A., and Thompson R. Pharmacokinetic effects of syringe mixing pramlintide, isophane insulin, and soluble insulin. Diabetologia 40 (1997) A356
116. Redalieu E., Dean E., Schoenfeld S., and Thompson R. Effects of syringe mixing pramlintide with regular and NPH insulin upon plasma glucose control in patients with type I diabetes. Can. J. Diabet. Care 21 (1997) 26
117. Rosenstock J., Whitehouse F., Schoenfeld S., Jeffcoate S., and Kolterman O. Results of 1-year study with pramlintide therapy in type 1 diabetes: Effect on metabolic control and safety profile. Can. J. Diabet. Care 22 (1998) A13
118. Rosenstock J., Whitehouse F., Schoenfeld S., Jeffcoate S., and Kolterman O. Results of 1-year study with pramlintide therapy in type 1 diabetes: Effect on metabolic control and safety profile. Diabetologia 41 (1998) A239
119. Samsom M., Szarka L.A., Camilleri M., Vella A., Zinsmeister A.R., and Rizza R.A. Pramlintide, an amylin analog, selectively delays gastric emptying: Potential role of vagal inhibition. Am. J. Physiol. 278 (2000) G946-G951
120. Samsom M., Szarka L.A., Vella A., Daniel D.A., Burton D., Thomforde G.M., Zinsmeister A.R., Rizza R.A., and Camilleri M. Effects of the amylin analog, pramlintide, on gastrointestinal and colonic transit in healthy subjects: Association with vagal inhibition. Gastroenterology 118 (2000) A-625
121. Schmitz O., Nyholm B., Orskov L., Gravholt C., and Moller N. Effects of amylin and the amylin agonist pramlintide on glucose metabolism. Diabetic Med. 14 (1997) S19-S23
122. Schoenfeld S., Dean E., Blonde L., and Kolterman O. Effects of syringe mixing pramlintide with regular and NPH insulin upon plasma glucose control in people with type 1 diabetes [in French]. Diabet. Metab. 24 (1998) LXXVIII
123. Thompson R., and Kolterman O. Intravenous pramlintide reduced postprandial hyperglycaemia and C-peptide concentrations in patients with type II diabetes mellitus [in French]. Diabet. Metab. 23 (1997) P054
124. Thompson R.G., Gottlieb A.B., Organ K., and Kolterman O.G. The human amylin analogue (AC137) reduces glucose following Sustacal in patients with type II diabetes. Diabetes 44 (1995) 127A
125. Thompson R.G., Organ K., Gottlieb A., and Kolterman O.G. Pramlintide (AC137) reduced postprandial hyperglycaemia, insulin, and C-peptide in patients with type II diabetes. Diabet. Med. 12 (1995) S46
126. Thompson R., Pearson L., Schoenfeld S., and Kolterman O. Pramlintide improves glycemic control in patients with type II diabetes requiring insulin. Diabetologia 40 (1997) A355
127. Thompson R.G., Gottlieb A., Organ K., Koda J., Kisicki J., and Kolterman O.G. Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet. Med. 14 (1997) 547-555
128. Thompson R.G., Peterson J., Gottlieb A., and Mullane J. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: Results of a multicenter trial. Diabetes 46 (1997) 632-636
129. Thompson R.G., Pearson L., Gottlieb A., and Kolterman O.G. Pramlintide, an analog of human amylin, reduced fructosamine in patients with Type I diabetes. Diabetes 45 (1996) 222A
130. Thompson R., and Kolterman O.G. Intravenous pramlintide reduced postprandial hyperglycaemia and C-peptide concentrations in patients with type II diabetes mellitus. Diabetic Med. 14 (1997) S41
131. Thompson R., Kolterman O., Peterson J., and Pearson L. Pramlintide reduced 24-hour glucose and serum fructosamine concentrations in people with type I diabetes mellitus. Can. J. Diabet. Care 21 (1997) 26
132. Thompson R., Kolterman O., Peterson J., and Pearson L. Pramlintide reduced 24-hour glucose concentrations and serum fructosamine in patients with Type I diabetes mellitus [in French]. Diabet. Metab. 23 (1997) P053
133. Thompson R.G., Pearson L., and Kolterman O.G. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: Effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia 40 (1997) 1278-1285
134. Thompson R.G., Pearson L., Schoenfeld S.L., and Kolterman O.G. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabet. Care 21 (1998) 987-993
135. U.K. Prospective Diabetes, Study (UKPDS), Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
136. UK Prospective Diabetes, Study (UKPDS), Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
137. Unger R.H., Aguilar-Parada E., Muller W.A., and Eisentraut A.M. Studies of pancreatic alpha cell function in normal and diabetic subjects. J. Clin. Invest. 49 (1970) 837-848
138. Vella A., Lee J.S., Camilleri M., Szarka L.A., Burton D.D., Zinsmeister A.R., Rizza R.A., and Klein P.D. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol. Motil. 14 (2002) 123-131
139. Want L.L. Pramlintide reduced postprandial glucose excursions without increasing severe hypoglycemia in patients with type 1 diabetes treated with CSII. Program Book AADE's 29th Annual Meeting and Exhibition (2002) 125-129
140. Want L.L., Levetan C., Weyer C., Maggs D.G., Crean J., Wang Y., Strobel S., Schoenamsgruber E., Kolterman O.G., Chandran M., Henry R.R., and Mudaliar S. Reduced postprandial glucose, glucagon and triglyceride excursions following 4 weeks of pramlintide treatment in patients with type 1 diabetes treated intensively with insulin pumps. Diabetes 51 suppl. 2 (2002) A117
141. Want L.L., Ratner R.E., and Uwaifo G.I. Safety and tolerability of long-term pramlintide therapy. Diabetes 53 suppl. 2 (2004) A150
142. Weyer C., Maggs D.G., Fineman M.S., Burrell T., and Kolterman O.G. The human amylin analog, pramlintide, reduces body weight in insulin-treated patients with type 2 diabetes. Int. J. Obes. 26 suppl. 1 (2002) abstract 508.
143. Weyer C., Kim D., Burrell T., Wang Y., Kornstein J., Bicsak T., Fineman M., Ruggles J., Schwartz S., and Kolterman O. Mealtime amylin replacement with pramlintide markedly reduced postprandial glucose excursions when added to insulin lispro in patients with type 1 or type 2 diabetes: A dose-timing study. Diabetes 52 suppl. 1 (2003) A16
144. Weyer C., Fineman M., Burrell T., Strobel S., Shen L., and Kolterman O. Adjunctive therapy with pramlintide lowers A1c without concomitant weight gain in patients with type 2 diabetes approaching ADA glycemic targets. Diabetes 52 suppl. 1 (2003) A138
145. Weyer C., Fujioka K., Aroda V., Edelman S., Chen K., Lush C., Wang Y., Burns C., Lutz K., McIntyre S., Kornstein J., Wintle M., and Baron A. Safety, dose-tolerance, and weight-related effects of pramlintide in obese subjects with or without type 2 diabetes. Endocrine Society Program & Abstracts 87th Annual Meeting, San Diego, June 4-7 (2005)
146. Weyer C., Aronne L., Fujioka K., Aroda V., Edelman S., Chen K., Lush C., Wang Y., Burns C., Lutz K., McIntyre S., Kornstein J., Wintle M., and Baron A. Safety, dose-tolerance, and weight-related effects of pramlintide in obese subjects with or without type 2 diabetes. Abstract presented at 14th European Congress on Obesity; 2005 Jun 1-4; Athens, Greece (2005)
147. Whitehouse F., Kruger D.F., Fineman M., Shen L., Ruggles J.A., Maggs D.G., Weyer C., and Kolterman O.G. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabet. Care 25 (2002) 724-730
148. Wilding J.P.H., Khandan-Nia N., Bennet W.M., Gilbey S.G., Beacham J., Ghatei M.A., and Bloom S.R. Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia 37 (1994) 166-169
149. Wilding J.P.H., Khandan-Nia N., Gilbey S.G., Bennet W.M., Beacham J., Ghatei M.A., and Bloom S.R. Amylin does not affect insulin sensitivity in man. Br. Diabet. Assn (1993)
150. Wimalawansa S.J., Gunasekera R.D., and Datta H.K. Hypocalcemic actions of amylin amide in humans. J. Bone Miner. Res. 7 (1992) 1113-1116
151. Weyer C., Maggs D.G., Fineman M., Gottlieb A.D., Shen L.Z., and Kolterman O.G. Amylin replacement with pramlintide as an adjunct to insulin therapy facilitates a combined improvement in glycemic and weight control in type 1 diabetes. Diabetologia 44 suppl. 1 (2001) A237
152. Weyer C., Maggs D.G., Young A.A., and Kolterman O.G. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control [published correction appears in Curr. Pharm. Des. 2001; 7, 1967]. Curr. Pharm. Des. 7 (2001) 1353-1373
153. Young A., Nuttall A., Moyses C., Percy A., Vine W., and Rink T. Amylin stimulates the renin-angiotensin-aldosterone axis in rats and man. Diabetologia 38 (1995) A225
154. Young A., Kolterman O., and Hall J. Amylin innocent in essential hypertension?. Diabetologia 42 (1999) 1029